Bambusa Therapeutics, Inc. (NASDAQ:BBTX – Get Free Report) Director Helmut Wolfgang Jeggle acquired 375,000 shares of the firm’s stock in a transaction that occurred on Monday, November 2nd. The shares were bought at an average price of $16.00 per share, with a total value of $6,000,000.00. Following the acquisition, the director directly owned 9,264,301 shares in the company, valued at $148,228,816. This represents a 4.22% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Bambusa Therapeutics Stock Performance
BBTX traded up $1.01 during trading on Monday, hitting $16.00. 433,191 shares of the stock were exchanged. Bambusa Therapeutics, Inc. has a 1 year low of $13.60 and a 1 year high of $16.06.
Recommended Stories
- Five stocks we like better than Bambusa Therapeutics
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for Bambusa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bambusa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
